Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

84.02 +0.31 (+0.37%)
Official Closing Price Updated: 7:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
Gamestop, FST Corp, Merck, UPS, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market had a mixed session on Tuesday. The Nasdaq Composite climbed nearly 80 points, or 0.5%, closing at 18,271.86, while the Dow remained largely flat at 42,587.50. The S&P 500 edged... 
Via Benzinga
Topics Stocks
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
Via The Motley Fool
What's going on in today's session: S&P500 movers
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
Tuesday's session: top gainers and losers in the S&P500 index
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
Merck & Co Unusual Options Activity For March 10
Via Benzinga
Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed
The Chinese company will receive $200 million upfront and will be eligible to earn up to $1.77 billion in milestone payments and royalties on net sales of the drug, if approved. 
Via Stocktwits
Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment
Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion. 
Via Benzinga
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for melanoma continue into 2025. 
Via Benzinga
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics
Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space. 
Via Benzinga
Which S&P500 stocks are gapping on Monday?
Curious about the S&P500 stocks that are gapping on Monday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
1 Value Stock with Solid Fundamentals and 2 to Turn Down
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
2 Beaten-Down Stocks to Buy on the Dip
Via The Motley Fool
“We’re In A Stock Pickers Market”
Markets have been oscillating up and down for weeks, creating what resembles a sine wave pattern. As the analyst notes, 
Via Talk Markets
Topics ETFs
Which Is The Healthiest Investment: Merck Or Pfizer
Adeep dive into Merck and Pfizer, two of the biggest pharmaceutical companies out there. 
Via Talk Markets
Topics Stocks / Equities
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial. 
Via Benzinga
Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock.
Balancing Dividends and Fundamentals: The Case of MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
A Closer Look at Merck & Co's Options Market Dynamics
Via Benzinga
These S&P500 stocks are gapping in today's session
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends. 
Via Chartmill
Inflation Isn’t Going Away, But These Sectors Don’t Care
The CPI and PPI releases this week came in more or less at estimates - nothing to alarm the talking heads, anyway. They show inflation slowing down but not receding. 
Via Talk Markets
Topics ETFs Economy Stocks / Equities
How Do Investors Really Feel About Merck & Co?
Via Benzinga
Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025
Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for mid-2025. 
Via Benzinga
Merck Injects $1 Billion To Expand Vaccine Production In US
Merck unveils a $1 billion vaccine manufacturing facility in Durham, North Carolina, expanding its U.S. production and research investments. 
Via Benzinga
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains. 
Via MarketBeat
Institutional Investors Bet $1B on These 4 Stocks—Should You?
Institutional investors snapped up at least $1 billion in shares of each of these four companies in Q4 of 2024 - should you buy as well? 
Via MarketBeat
3 Magnificent S&P 500 Dividend Stocks Down 20% to 63% to Buy and Hold Forever
Great investments are even better and more fruitful when you can buy them at a discount. 
Via The Motley Fool
Topics Stocks
5 Top Stocks to Buy for March
These 5 stocks look rather intriguing at current levels. 
Via The Motley Fool
In a market where value is scarce, MERCK & CO. INC. (NYSE:MRK) offers a refreshing opportunity with its solid fundamentals.
Discover MERCK & CO. INC., an undervalued stock. NYSE:MRK showcases solid financial health and profitability while maintaining an appealing valuation. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.